Both in Pharmaceuticals
AN2 Therapeutics vs Cue Biopharma
Over the past year ANTX returned +263.5% and CUE returned −3.1%; their daily moves had a correlation of 0.06.
ANTX +263.5% CUE −3.1%Growth of $1, one year, split-adjusted
| Metric | ANTX | CUE |
|---|---|---|
| Price | $4.18 | $20.86 |
| Market cap | $157.7M | $151.5M |
| Today | −3.91% | +7.42% |
| 1 month | −25.5% | −14.4% |
| 6 months | −10.9% | −40.3% |
| Year to date | +266.7% | +127.7% |
| 1 year | +239.8% | −9.4% |
| Revenue growth (YoY) | — | +166.7% |
| Gross margin | — | 100.0% |
| Net margin | — | −1943.2% |
| P/E (TTM) | — | — |
| Price / sales | — | 4.0× |
| Net cash | $78.4M | $16.4M |
| Dividend yield | — | — |
| Volatility (60d) | 75.1% | 138.5% |
| Short % of float | 10.0% | 12.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).